Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$57.02
pos +0.00
+0.00%
Today's Range: 56.45 - 57.20 | TEVA Avg Daily Volume: 4,170,400
Last Update: 02/27/15 - 4:01 PM EST
Volume: 0
YTD Performance: -0.85%
Open: $0.00
Previous Close: $56.49
52 Week Range: $47.36 - $61.90
Oustanding Shares: 851,871,888
Market Cap: 48,122,242,953
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 11 11
Moderate Buy 1 1 1 1
Hold 10 10 10 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.95 1.95 1.95 1.95
Latest Dividend: 0.29
Latest Dividend Yield: 2.04%
Dividend Ex-Date: 02/17/15
Price Earnings Ratio: 37.91
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
37.91 15.90 26.52
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.37% 15.68% 28.48%
GROWTH 12 Mo 3 Yr CAGR
Revenue -0.20 0.11 0.03
Net Income 142.80 0.10 0.03
EPS 138.50 0.15 0.05
Earnings for TEVA:
EBITDA 6.00B
Revenue 20.27B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $1.25 $1.28 $5.15 $5.14
Number of Analysts 11 9 14 12
High Estimate $1.38 $1.32 $5.30 $5.37
Low Estimate $1.17 $1.23 $5.04 $4.46
Prior Year $1.22 $1.23 $5.07 $5.15
Growth Rate (Year over Year) 2.53% 4.34% 1.54% -0.17%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Small-Cap Friday's Little Gem Real Money Pro($)

One small pharmaceutical company has big potential.

Take a Look at Teva Real Money Pro($)

We like new initiatives and see solid upside potential.
Bullish
Dec 12, 2014 | 8:15 AM EST
TEVA was upgraded from Neutral to Buy, Sterne Agee said. $65 price target. Estimates also upped, given the company's new guidance. ...

Merger Mania Benefits Mylan Real Money Pro($)

Whether it's acquiring or the acquired, Mylan is building shareholder value.
Investing during a mid-term election can offer large returns.
Bullish
Aug 04, 2014 | 7:56 AM EDT
TEVA price target raised from $50 to $54, UBS said. Neutral rating. Estimate also raised due to higher base sales.

Off the Charts Real Money Pro($)

We raised our stops on Teva and added Staples to the long ideas table.
It is preserving its Copaxone franchise, and the executive changes are good news.

Waiting for the Fed Real Money Pro($)

In a flattish market, transports are strong on FedEx's earnings, and small-caps are underperforming.
Conflicting technical patterns suggest one is healthy and the other could be under the weather.

Columnist Conversations

Reports on Tuesday. I am getting a little concerned on how the 2015 guidance will come in.
JCP
Soz doing some more good stuff on retail today-- I loved the JCP piece.. Remember you can follow a writer now ...
Despite a big upgrade from Credit Suisse(from Neutral to Outperform)FDX is relatively flat today. The st...
The Market Vectors Gold Miners ETF (GDX) chart continues to exhibit characteristics of a classic cup-and-handl...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.